November 12, 2012 - Joint ASM-CDC Developed Group B Streptococcus Protocols Now Available
Standard operating procedures for processing group B Streptococcus specimens are now available. These five protocols were developed collaboratively by the American Society for Microbiology (ASM) and the Centers for Disease Control and Prevention (CDC) Streptococcus Laboratory and are consistent with the recommendations in the 2010 GBS guidelines but are tailored for use in different settings, depending on the procedures and assays used in each laboratory (e.g. pigmented or non-pigmented broth, sub-culture versus serologic or molecular methods, etc.).
January 18, 2011 - A Quick Guide to the Significance and Laboratory Identification of Cryptococcus gattii
The PSAB Committee on Laboratory Practices has prepared A Quick Guide to the Significance and Laboratory Identification of Cryptococcus gattii. C.gattii has emerged as an important cause of cryptococcosis in the Pacific Northwest region of the U.S. This organism can not be differentiated from C. neoformans by conventional laboratory methods, and differences in clinical course and treatment outcomes have been suggested. This document outlines the epidemiological and clinical differences between C. gattii and C. neoformans, and indicates the laboratory tests that can be used for the differentiation of these two organisms. The document was drafted by Susan Butler-Wu and Ajit Limaye and reviewed by the PSAB Committees on Laboratory Practices and Professional Affairs.
January 12, 2011 - A Practical Guidance Document for the Laboratory Detection of Vibrio cholerae
The PSAB Committee on Laboratory Practices has prepared A Practical Guidance Document for the Laboratory Detection of Vibrio cholerae. Since cholera was reported in Haiti on October 21, 2010 following a devastating earthquake, aid workers from the U.S. and other countries have been traveling to Haiti in order to provide medical care and other assistance. These workers are at risk of acquiring cholera and returning to their home countries with infection. This document was developed to help laboratories understand how to accurately and rapidly identify V. cholerae. The document was drafted by Barbara Robinson-Dunn and Christopher Doern and reviewed by the PSAB Committees on Laboratory Practices and Professional Affairs.
September 21, 2010 – A Practical Guidance Document for the Laboratory Detection of Toxigenic Clostridium difficile – REVISED*
The PSAB Committee on Laboratory Practices prepared A Practical Guidance Document for the Laboratory Detection of Toxigenic Clostridium difficile to help laboratories understand that using toxin testing alone is not sufficient for accurate detection. Bulleted highlights for C. difficile laboratory testing lead the discussion and several sample testing algorithms are included. The document was drafted by Susan Sharp, Ph.D., Chair, PSAB Committee on Laboratory Practices and Peter Gilligan, Ph.D., Dean, American College of Microbiology and reviewed by the PSAB Committees on Laboratory Practices and Professional Affairs. *This document was updated on September 21 to replace the September 9, 2010 version.
July 28, 2010 - How Microbiology Cultures Complement Molecular Infectious Disease Testing
On July 28, 2010, the ASM participated in the American Association for Clinical Chemistry’s Annual Meeting for a PSAB sponsored session, How Microbiology Cultures Complement Molecular Infectious Disease Testing. Presentations focused on advancements in molecular infectious disease diagnosis, as well as how more traditional testing methods such as culture are still utilized and may perform better than or be used in conjunction with molecular techniques.
Detecting Clostridium difficile: What, When and Why? – presented by Susan E. Sharp, Ph.D.
The Future of TB Testing – presented by E.J. Baron, Ph.D.
Diagnosis of Shiga Toxin- Producing E. coli (STEC) Infections: A Multi-Faceted Approach – presented by Roberta B. Carey, Ph.D.
Influenza Antigen Testing: Helpful or Harmful? – presented by Kimberle Chapin, M.D.
Molecular Screening for MRSA: Impact on Patient Care – presented by Peter Gilligan, Ph.D.